Variant position: 172 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 638 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human PIALNWTLLNVSLTGIHADI QVRWEAPRNADIQKGWMVLEY
Rhesus macaque PIALNWTLLNVSLTGIHADI LVRWEAPPNADIQKGWMVLEY
Mouse PIGLNWTLLNISLTGIRGDI QVSWQPPPNADVLKGWIILEY
Rat PIGLNWTLLNISLPGIRGDI QVSWQPPPSADVLKGWIILEY
Pig PIGLNWTLLNISLTGIHADI QVRWEPPPNADVQKGWIVLEY
Bovine PVGLNWTLLNISLTEIHADI LVKWEPPPNTDVKMGWIILEY
Rabbit PIGLNWTLLNVSLTGIHADI QVRWEPPPNADVQKGWIVLEY
Sheep PVGLNWTLLNISLTEIHADI LVKWEPPPNTDVKMGWIILEY
Chicken PVHLNWTLLNTSQTGIHGDI QVRWDPPPTADVQKGWITLEY
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
19 – 638 Growth hormone receptor
19 – 256 Growth hormone-binding protein
19 – 264 Extracellular
151 – 254 Fibronectin type-III
156 – 156 N-linked (GlcNAc...) asparagine
161 – 161 N-linked (GlcNAc...) asparagine
167 – 176
Four contiguous amino acid substitutions, identified in patients with Laron syndrome, differently affect the binding affinity and intracellular trafficking of the growth hormone receptor.
Wojcik J.; Berg M.A.; Esposito N.; Geffner M.E.; Sakati N.; Reiter E.O.; Dower S.; Francke U.; Postel-Vinay M.-C.; Finidori J.;
J. Clin. Endocrinol. Metab. 83:4481-4489(1998)
Cited for: VARIANTS LARS HIS-170; THR-171; PRO-172 AND GLY-173; CHARACTERIZATION OF VARIANTS LARS THR-171; PRO-172 AND GLY-173;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.